ArticleJournal of molecular histology2026
CLEC14A mediates trophoblast dysfunction in unexplained miscarriage by disrupting the cAMP/ERK signaling pathway.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Unexplained miscarriage (UM) is a distressing pregnancy disorder often associated with impaired trophoblast function. This study aimed to investigate the role of C-type lectin domain family 14 member A (CLEC14A) in the pathogenesis of UM and to elucidate the underlying molecular mechanisms. Transcriptomic data from UM and healthy placental tissues (GSE123719) were analyzed. CLEC14A expression was validated in clinical chorionic villi samples (n = 10 per group) by immunohistochemistry, RT-qPCR, and Western blot. Gain-of-function studies were performed in HTR-8/SVneo trophoblast cells using lentiviral-mediated CLEC14A overexpression. Functional impacts on migration, invasion, and tube formation were assessed. RNA sequencing was used to identify dysregulated pathways, and key findings were confirmed by ELISA and Western blot. Rescue experiments were conducted using the adenylate cyclase inhibitor SQ22536. CLEC14A was significantly upregulated at both the mRNA and protein levels in villous tissues from UM patients compared to controls. In vitro, CLEC14A overexpression markedly suppressed trophoblast migration, invasion, and endothelial-like tube formation. Transcriptomic and mechanistic analyses revealed that CLEC14A overexpression activated the cAMP signaling pathway, leading to increased intracellular cAMP levels and Protein Kinase A (PKA) phosphorylation, while concurrently attenuating extracellular signal-regulated kinase (ERK) phosphorylation. The functional deficits and signaling perturbations induced by CLEC14A were effectively reversed by inhibition of cAMP synthesis. Our findings demonstrate that aberrant upregulation of CLEC14A impairs trophoblast function by activating the cAMP-PKA pathway and suppressing ERK signaling, thereby contributing to the pathogenesis of unexplained miscarriage. CLEC14A and its downstream signaling axis represent potential diagnostic and therapeutic targets for this condition.
Indexed as
Identifiers
42113307What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.